Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

May 11, 2020May 11, 2020

FDA Decision on Liso-cel, CAR T-cell Therapy for Large B-cell Lymphoma, Due in November

News

The U.S. Food and Drug Administration (FDA) has extended by three months its review of Bristol-Myers Squibb’s investigational CAR T-cell therapy, lisocabtagene maraleucel (liso-cel), as a treatment for adults with relapsed or refractory large B-cell lymphoma after at ... Read more

March 3, 2020March 3, 2020

Tessa’s CD30 CAR T-cell Therapy for Lymphoma Granted RMAT Status by FDA

News

The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Tessa Therapeutics’ investigational CD30-targeted CAR T-cell therapy for treating relapsed or refractory classical Hodgkin’s lymphoma. This ... Read more

January 7, 2020February 18, 2020

Bristol-Myers Seeks FDA Approval of CAR T-cell Therapy Liso-Cel for Aggressive Large B-cell Lymphomas

News

Bristol-Myers Squibb has asked the U.S. Food and Drug Administration (FDA) to approve its investigational CAR T-cell therapy lisocabtagene maraleucel (liso-cel) for people with large B-cell lymphoma who received at ... Read more

November 26, 2019November 26, 2019

FDA Approves Calquence as Treatment Option for Adults with CLL and SLL

News

The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Calquence (acalabrutinib) to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The agency’s decision was based ... Read more

November 22, 2019November 22, 2019

EU Advisory Committee Favors Approval of Polivy with MabThera and Bendamustine for Advanced DLBCL

News

An advisory committee for the European Medicines Agency has recommended the conditional approval of Roche‘s Polivy (polatuzumab vedotin) in combination with MabThera (rituximab) and bendamustine (a chemotherapy) for the treatment of ... Read more

November 15, 2019

Nanatinostat Combo Put on FDA’s Fast Track for Hard-to-treat Lymphomas Linked to EBV Infection

News

The U.S. Food and Drug Administration has granted fast track designation to a combination of Viracta Therapeutics‘ investigational therapy nanatinostat and the antiviral valganciclovir in treating relapsed or refractory lymphomas ... Read more

November 8, 2019

Advanced Follicular Lymphoma Patients Show Positive Overall Response to Umbralisib in Phase 2 Trial

News

TG Therapeutics’ umbralisib (TGR-1202), an inhibitor of the PI3K delta protein, has shown promising response rates in patients with relapsed or refractory follicular lymphoma, according to new data from a Phase ... Read more

November 5, 2019

Nektar Launches Phase 1 Trial Testing NKTR-255 in Non-Hodgkin’s Lymphoma, Multiple Myeloma

News

Nektar Therapeutics is launching a first-in-human Phase 1 clinical trial assessing the safety and efficacy of its investigational agent NKTR-255 in people with relapsed or refractory non-Hodgkin’s lymphoma and multiple ... Read more

November 1, 2019November 11, 2019

Copiktra May Be Treatment Option for Advanced Marginal Zone Lymphoma, Trial Data Show

News

Copiktra (duvelisib), developed by Verastem Oncology, may be an effective and reasonably safe treatment option for people with marginal zone lymphoma who failed to respond to prior therapies including rituximab, Phase 2 data ... Read more

October 31, 2019

Cirmtuzumab-Imbruvica Combo Trial Opens New Expansion Part for Mantle Cell Lymphoma

News

A Phase 1/2 trial assessing Oncternal Therapeutics‘ cirmtuzumab plus Imbruvica (ibrutinib) for the treatment of B-cell cancers is opening a Phase 1b extension part to continue studying the combination in people ... Read more